“…[1][2][3][4][5][6] For diseases affecting the posterior tissues of the eye, SCS administration offers compartmentalization of therapies away from anterior tissues and the potential for long-acting delivery to target tissues. 7,8 One disease that can affect posterior tissues and that is associated with considerable visual impairment is uveitis, which is characterized by inflammation of the uveal tract (ie, iris, ciliary body, and choroid) and adjacent structures. 1,3,9 Uveitis can result from either infectious or noninfectious (eg, autoimmune) processes.…”